IN THE CLAIMS:

Claims 18-24 were previously cancelled. Claims 4, 17, 26, 35, and 36 are cancelled herein. Claims 1-3, 5, 7-14, 25, 27-29, and 37 have been amended herein. All of the pending claims 1-3, 5-16, 25, 27-34, 37, and 38 are presented below. This listing of claims will replace all prior versions and listings of claims in the application. Please enter these claims as amended.

Listing of Claims:

1. (currently amended) A method for producing [[a]] an influenza virus and/or influenza viral protein ~~proteins other than adenovirus or adenoviral proteins~~ for use as a vaccine, said method comprising:

providing a cell with at least a sequence encoding at least one gene product of the E1 gene ~~or a functional derivative thereof of~~ of an adenovirus, wherein said cell is a human embryonic retinoblast;

~~providing~~ infecting said cell with ~~a nucleic acid encoding said non-adenovirus and/or said non-adenoviral proteins~~ an influenza virus;

culturing said cell in a suitable medium and allowing for expression of said ~~non-adenovirus and/or said non-adenoviral proteins~~ influenza virus and/or influenza viral protein; and

harvesting said ~~non-adenovirus and/or said non-adenoviral proteins~~ influenza virus and/or influenza viral protein from said suitable medium and/or said cell.

2. (currently amended) The method according to claim 1 wherein said cell that is to be provided with a sequence encoding said gene product of the E1 gene of an adenovirus is a ~~human~~ primary cell.

3. (currently amended) The method according to claim 2 wherein said ~~human primary~~ cell is immortalized by [[a]] said gene product of the E1 gene.

4. (cancelled)

5. (currently amended) The method according to claim 2 wherein said at least a sequence encoding said least one gene product of the E1 gene is present in [[a]] the genome of said ~~human primary~~ cell.

6. (previously presented) The method according to claim 1 wherein said cell does not produce adenoviral structural proteins.

7. (currently amended) The method according to claim 2 wherein said cell further comprises a sequence encoding adenovirus E2A ~~or a functional derivative, analogue or fragment thereof~~.

8. (currently amended) The method according to claim 7 wherein said sequence encoding E2A ~~or a functional derivative, analogue or fragment thereof,~~ is present in [[a]] the genome of said ~~human primary~~ cell.

9. (currently amended) The method according to claim 7 wherein said sequence encoding E2A ~~or a functional derivative, analogue or fragment thereof,~~ encodes a temperature-sensitive mutant E2A.

10. (currently amended) The method according to claim 2 wherein said ~~human primary~~ cell comprises no other adenoviral sequences.

11. (currently amended) The method according to claim 2 wherein said ~~human primary~~ cell is grown in suspension.

12. (currently amended) The method according to claim 2 wherein said ~~human primary~~ cell is cultured in the absence of serum.

13. (currently amended) The method according to claim 2 wherein said ~~human primary~~ cell that is provided with at least a sequence encoding at least one gene product of the E1 gene of an adenovirus is PER.C6 as deposited under ECACC no. 96022940 ~~or derivative thereof~~.

14. (currently amended) The method according to claim 1 wherein said influenza virus and/or said influenza viral proteins comprise a protein that undergoes post-translational and/or peri-translational modifications.

15. (previously presented) The method according to claim 14 wherein said post-translational and/or peri-translational modifications comprise glycosylation of a viral protein.

16. (previously presented) The method according to claim 1 wherein said viral proteins comprise at least one of an influenza virus neuramidase or a hemagglutinin.

17. (cancelled)

18-24. (cancelled)

25. (currently amended) ~~An improvement in a~~ A process for producing ~~a non-adenovirus or non-adenoviral~~ influenza virus or influenza viral protein for use in a vaccine for use in a human subject, said process ~~being of the type wherein a cell line is infected with a virus, said improvement~~ comprising the steps of:

~~using, as said cell line in said process,~~ culturing a human cell line having a sequence encoding at least one E1 protein of an adenovirus ~~or a functional derivative, homologue or fragment thereof~~ in its genome~~,~~; and

infecting said cell line with an influenza virus;

~~in which~~ wherein said human cell line is an embryonic retinoblast cell line and does not produce structural adenoviral proteins.

26. (cancelled)

27. (currently amended) The ~~improvement~~ process of claim 25 wherein said human cell line is a PER.C6 cell line ~~or a derivative thereof~~ as represented by the cells deposited under ECACC no. 96022940.

28. (currently amended) The ~~improvement~~ process of claim 25 wherein said human cell line further comprises a sequence encoding adenoviral E2A ~~or a functional derivative, analogue or fragment thereof~~ in its genome.

29. (currently amended) The ~~improvement~~ process of claim 28 wherein said adenoviral E2A is temperature sensitive.

30. (withdrawn) A non-adenoviral virus or non-adenoviral protein for use in a vaccine produced by the process of claim 1, said virus or said viral protein being free of any non-human mammalian proteinaceous material.

31. (withdrawn) A human cell having a sequence encoding at least on E1 protein of an adenovirus or a functional derivative, homologue or fragment thereof in its genome, which human cell does not produce structural adenoviral proteins, and said human cell further having a nucleic acid encoding a virus or at least one non-adenoviral protein.

32. (withdrawn) The human cell of claim 31 which is derived from PER.C6 as deposited under ECACC no. 96022940.

33. (withdrawn) The human cell of claim 31, which further comprises a sequence encoding adenoviral E2A or a functional derivative or analogue or fragment thereof in the human cell's genome.

34. (withdrawn) The human cell according to claim 33, wherein said adenoviral E2A is temperature sensitive.

35-36. (cancelled)

37. (currently amended) The method according to claim 1, wherein said sequence encoding the at least one gene product of the E1 gene comprises a plasmid comprising an Ad serotype 5 (Ad5) E1A- and E1B-coding sequence (Ad5 nucleotides 459-3510).

38. (previously presented) The method according to claim 25, wherein said viral protein is selected from the group consisting of influenza surface antigens consisting of surface glycoproteins, hemagglutinin and neuraminidase.